Key facts
- It has raised $91.8M; the latest was Later Stage VC ($87.0M) in Mar 2026.
- Notable investors include F-Prime Capital, Qiming Venture Partners, Parkwalk Advisors, Cambridge Enterprise Ventures, MNL Nominees — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Immutrin
- ·The full record, as it builds
Funding rounds
No funding rounds for Immutrin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immutrin
Developer of antibody-based therapies intended to treat amyloidosis by removing systemic amyloid deposits. The company offers targeted antibodies with selective fibril-binding mechanisms, enabling researchers and healthcare providers to address amyloid-related diseases and improve disease management.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2019
- Employees
- 8
- Website
- immutrin.com/
- Ownership
- Privately Held (backing)
Immutrin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immutrin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immutrin in its N-PORT filings yet. We sweep new filings monthly.